CA-INFOGAIN
4.1.2022 06:39:11 CET | Business Wire | Press release
Infogain, a Silicon Valley-based global leader in human-centered digital platform engineering services, has appointed Dayapatra Nevatia as President and Chief Operating Officer, responsible for global operations. Reporting to CEO Ayan Mukerji, he will support and execute Infogain’s strategy of combining cloud, experience, and AI to build innovative human-centered digital solutions for our customers.
Nevatia is a well-respected IT industry veteran with close to three decades of experience in client value creation and delivery, incubating new business verticals, managing large P&Ls, and leading culturally diverse global organizations with more than 100,000 global team members. In his most recent role as Mindtree’s Executive Director and Chief Operating Officer, he was responsible for designing, planning, and implementing business strategies and operating plans that align with the company’s vision and long-term goals.
Prior to Mindtree, Nevatia served in senior leadership roles at Accenture for many years. As Managing Director and Director of Delivery for Advanced Technology Centres in India for Accenture, he was part of their Indian executive leadership team, delivering programs in system integration, application outsourcing, infrastructure, digital, and security services across different industry groups.
Infogain CEO Ayan Mukerji said, “Dayapatra brings deep knowledge of managing growth and scale with a solid understanding of technology. Infogain will benefit from this expertise. His addition to our executive leadership team will also add a new perspective and enhance our ability to solve complex business challenges facing our customers today.”
Mukerji continued, “I’d also like to thank Eddie Chandhok for his 18 years of outstanding performance nurturing our organization’s growth. Eddie will stay on with the company and continue to drive Infogain’s M&A function, which is increasingly becoming more strategic as we continue to bring on new talent and integrate new global delivery locations.”
Dayapatra added, “I am excited to be joining a rapidly growing digital engineering company like Infogain, with futuristic leaders who are all-in, building platforms that drive our customers' business.”
Shashank Singh, Partner at Apax, which advises funds that are majority owners of Infogain, said, “Dayapatra’s impressive background and experience working with CEOs, CDOs, and CTOs of Fortune 100 companies make him a great fit for taking Infogain’s delivery and operations to the next level.”
Rohan Haldea, Partner at Apax, added, “This is another exciting step in Infogain’s growth journey and will drive performance excellence in the global team.”
Dayapatra has a bachelor’s degree in Electronics Engineering from IET, Lucknow, and a master’s degree in General Management from IISc, Bangalore.
About Infogain
Infogain is a human-centered digital platform engineering company based out of Silicon Valley. We engineer business outcomes for Fortune 500 companies and digital natives in the technology, healthcare, insurance, travel, telecom, and retail/CPG industries. We accelerate experience-led transformation in the delivery of digital platforms using technologies such as cloud, microservices, automation, IoT, and artificial intelligence. Infogain is a multi-cloud expert across hyperscale cloud providers – Microsoft Azure, Google Cloud Platform, and Amazon Web Services.
Infogain, an Apax Funds portfolio company, has offices in California, Washington, Texas, the UK, the UAE, and Singapore, with delivery centers in Seattle, Houston, Austin, Kraków, Noida, Bengaluru, Pune, Gurgaon, and Mumbai. To learn more, visit www.infogain.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220103005521/en/
Social Media:
https://www.facebook.com/pages/Enterprise-IT-CompanyInfogain/245846616349?ref=ts
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom